INTRODUCTIONHelicobacter pylori infection is the most common cause of nonautoimmune chronic active gastritis. Almost all duodenal ulcer patients without exposure to nonsteroidal anti-in¯ammatory drugs are infected with H. pylori. It is well known that the eradication of this bacterium heals duodenal ulcers and drastically reduces the relapse rate from over 80% to less than 5% a year. 1 The current popular protocols for H. pylori eradication regimens consist of an acid suppressant (most commonly being omeprazole) and two antibiotics such as clarithromycin and metronidazole (the so-called`Italian triple') or clarithromycin and amoxycillin (`French triple'). 2 The macrolide clarithromycin, element of either regimen, has been documented to be effective against H. pylori in vivo, even in the absence of an acid SUMMARY Background: The most extensively studied Helicobacter pylori eradication regimen comprises omeprazole, clarithromycin and metronidazole. Macrolide antibiotics other than clarithromycin should achieve similar ef®-cacy, but they have not yet been thoroughly tested. Aim: To determine the ef®cacy and safety of a triple therapy regimen using lansoprazole, roxithromycin, and metronidazole on the basis of multicentre outpatient care in an open pilot study. Methods: 163 patients with duodenal ulcer and proven H. pylori infection received lansoprazole 30 mg b.d., roxithromycin 300 mg b.d. and metronidazole 500 mg b.d. for 7 days followed by another 7 days of lansoprazole 30 mg once daily. H. pylori status was determined by urease quick test, histology, microbiology and 13 Curea breath test before starting and at least 4 weeks after completing treatment. Results: 150 patients were available for evaluation; H. pylori was successfully eradicated in 84.7% (127/